Table 4.

Neonates with clinically inapparent congenital CMV infection who received antiviral therapy

No. of patient	Site	Gestational age (week)	Weight (gram)	Sex	Abnormality	Therapy, duration
1	Dallas	37	2770	M	Lenticulostriate vasculopathy, elevated ALT	Ganciclovir, 6 weeks
2	Dallas	29	860	M	Thrombocytopenia, ventriculomegaly, diffuse cerebral calcifications, IVH grade I	Ganciclovir, 6 weeks
3	Dallas	41	3295	M	Elevated ALT, IVH grade I, hearing loss	Valganciclovir, 6 weeks
4	Dallas	37	2464	F	IVH grade I, hearing loss	Valganciclovir, 6 weeks
5	Buenos Aires	34	1910	F	Anemia and thrombocytopenia	Ganciclovir, 14 days Valganciclovir, 6 months
6	Buenos Aires	40	3150	F	None	Valganciclovir, 6 months
7	Buenos Aires	40	3977	F	None	Valganciclovir, 6 months
8	Buenos Aires	40	3475	F	None	Valganciclovir, 6 months
9	Buenos Aires	38	2950	M	Anemia, lenticulostriate vasculopathy, thalamic calcifications	Valganciclovir, 6 months
10	Buenos Aires	40	3300	M	Thrombocytopenia	Valganciclovir, 6 months
11	Buenos Aires	38	2820	M	Elevated ALT	Valganciclovir, 6 months
12	Buenos Aires	30	1500	M	Lenticulostriate vasculopathy	Ganciclovir, 14 days Valganciclovir, 6 months
13	Buenos Aires	34	1760	M	Elevated ALT, lenticulostriate vasculopathy, thalamic calcifications	Ganciclovir, 14 days Valganciclovir, 6 months
14	Buenos Aires	38	3400	M	Elevated ALT	Valganciclovir, 6 months
15	Buenos Aires	38	2865	M	Elevated ALT	Valganciclovir, 6 months
16	Buenos Aires	38	2530	M	Elevated ALT	Valganciclovir, 6 months
17	Buenos Aires	38	3310	M	Elevated ALT, periventricular calcifications and temporal lobe hyperechogenicity	Valganciclovir, 6 months
18	Buenos Aires	27	1216	M	Anemia, IVH grade II–III, hearing loss	Ganciclovir, 14 days Valganciclovir, 6 months

ALT alanine aminotransferase, IVH intraventricular hemorrhage